Stock Ratings / Health Care / LXEO / financials

OCGN (35) FATE (40) LCTX (29) IPSC (28) ⌘ Pro Terminal →

Lexeo Therapeutics Inc. (LXEO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$3.06 -2.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Lexeo Therapeutics Inc. (LXEO) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $251.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LXEO)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How LXEO Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-2.7%	-$100.0M	-$99.0M	-45%
FY 2024	$4.00B	52%	-2.6%	-$98.3M	-$81.6M	-45%
FY 2023	$4.00B	52%	-1.7%	-$66.4M	-$59.5M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LXEO)

✓Walkthrough of LXEO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LXEO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -46.32%▼ DESCENDING CHANNEL

2026-10-30O $3.02H $3.30L $2.90C $3.06VOL 1.00M

RES: $4.66SUP: $2.40SMA50: $3.75SMA200: $5.21

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LXEO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LXEO Butterfly Map → + Track LXEO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LXEO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LXEO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LXEO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LXEO)

Health Care Rank #783 of 1016 ⚔️ OCGN vs LXEO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LXEO vs. OCGN, FATE, LCTX, IPSC)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lexeo Therapeutics Inc. (LXEO) ranks #783 by composite RQD confidence (36/100, grade D-) and #547 by equity capitalization ($251.1M). Within this direct 5-issuer industry benchmark cohort, LXEO leads on earnings valuation at N/A trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. FATE currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with LXEO at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LXEO ACTIVE Lexeo Therapeutics Inc.	D-	36/100	—	—	-35.0%	-2.24%	$251.1M	Benchmark Subject
OCGN Ocugen Inc.	D-	35/100	—	—	-35.0%	-4.15%	$252.4M	/ocgn-vs-lxeo →
FATE Fate Therapeutics Inc.	D-	40/100	—	—	-35.0%	0.00%	$260.0M	/fate-vs-lxeo →
LCTX Lineage Cell Therapeutics Inc.	E	29/100	—	—	-35.0%	-0.96%	$260.5M	/lctx-vs-lxeo →
IPSC Century Therapeutics Inc.	E	28/100	—	—	-14.1%	-2.67%	$264.4M	/ipsc-vs-lxeo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001907108

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lexeo Therapeutics Inc. (LXEO) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$100.0M, operating cash flow of -$98.6M, and free cash flow of -$99.0M (-21.2% YoY). On the balance sheet, LXEO closed FY2025 with $268.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$100.0M	-$98.6M	-$99.0M	$268.7M	—
FY2024 (FY)	2024-12-31	$0	-$98.3M	-$81.2M	-$81.6M	$146.9M	—
FY2023 (FY)	2023-12-31	$0	-$66.4M	-$59.5M	-$59.5M	—	—

3. LXEO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LXEO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Lexeo Therapeutics Inc. (NASDAQ: LXEO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $3.06 (-2.24% 1D, market cap $251.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LXEO ranks #783 in composite RQD confidence.

How does LXEO compare to OCGN and FATE in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LXEO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OCGN (Ocugen Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $252.4M) and FATE (Fate Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $260.0M). Among the 5-stock peer group, LXEO leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LXEO?

Per LXEO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001907108), Lexeo Therapeutics Inc. generated $0 in revenue, -$100.0M in net income, and -$99.0M in free cash flow against $268.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LXEO trading relative to its 50-day, 200-day, and 52-week technical levels?

LXEO last traded at $3.06 (-2.24% on volume of 1,046,027 shares), positioning the stock -18.40% below its 50-day simple moving average ($3.75) and -41.27% below its 200-day simple moving average ($5.21). Across its 52-week range of $2.55 to $10.99, LXEO sits at the 6.0% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.68 to $3.44).